Is Alkem Laboratories (ALKEM) overvalued or fairly valued?

MarketChacha shows Alkem Laboratories's valuation in context — a forward P/E of about 25.0, a price-to-book of about 4.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Alkem Laboratories's revenue?

Alkem Laboratories reported revenue of ₹14,712 Cr for FY2026, with net profit of ₹2,302 Cr, per official filings.

What is the share price of Alkem Laboratories (ALKEM)?

Alkem Laboratories last traded at ₹5,648.00 (+1.5% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Alkem Laboratories

ALKEM · NSE · Pharma · India

₹5,648.00+1.5%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:34 AM

Snapshot

TickerALKEM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersMumbai, India

Market cap₹67,596 Cr

P/B4.9

Volume5.77K

Websitewww.alkemlabs.com

Filings tracked0

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters62.4%
Institutions26.3%
Public & other11.2%

158 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend8.5% → 15.6%

Margin has expanded by about 7.2 points — the business is getting more profitable.

Growth qualityrev 8% · PAT 33%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,456 Cr · EPS 59.00

Est. earnings growth -7.8%

Next fiscal year

Rev ₹18,217 Cr · EPS 226.20

Est. earnings growth +15.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹4,738.5052-wk range₹5,933.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹67,596 Cr

Day change

+1.5%

Fwd P/E

25.0

P/B

4.9

Div yield

0.36%

Beta

0.27

Revenue (FY2026)

₹14,712 Cr

Net margin

15.6%

Revenue CAGR (3y)

+8.2%

Profit CAGR (3y)

+32.7%

Net profit (FY2026)

₹2,302 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ALKEM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹14,712 Cr	₹2,302 Cr	15.6%
FY2025	₹12,965 Cr	₹2,165 Cr	16.7%
FY2024	₹12,668 Cr	₹1,796 Cr	14.2%
FY2023	₹11,599 Cr	₹984 Cr	8.5%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹3,603 Cr	₹236 Cr	6.6%
2025Q4	₹3,737 Cr	₹636 Cr	17.0%
2025Q3	₹4,001 Cr	₹765 Cr	19.1%
2025Q2	₹3,371 Cr	₹664 Cr	19.7%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.